Rutin Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 370

Clinical Trials

Numerous clinical trials spanning Phase 1 through Phase 4 evaluate Rutin across vascular, metabolic, and oncological conditions, including chronic venous insufficiency, hemorrhoidal disease, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and muscle-invasive bladder cancer. Predominantly sponsored by academic institutions and medical centers, these studies encompass completed, recruiting, not yet recruiting, and withdrawn recruitment statuses.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07310407	NOT_YET_RECRUITING	NAFLD	Ain Shams University	2026-01-01	PHASE2
NCT06718452	NOT_YET_RECRUITING	Tinnitus; Neuroinflammation	University of Campania Luigi Vanvitelli	2026-04-20
NCT07689214	RECRUITING	Diabete Type 2	University of Roma La Sapienza	2024-07-17
NCT07564999	ENROLLING_BY_INVITATION	The Aim is to Strengthen Disaster Preparedness Knowledge and Skills Through Peer Interaction	Selcuk University	2026-05-15
NCT06916494	RECRUITING	Muscle Invasive Bladder Cancer	First Affiliated Hospital of Chongqing Medical University	2025-05-01	PHASE1
NCT06705777	COMPLETED	Haemorrhoidal Disease	Fundação Educacional Serra dos Órgãos	2024-09-01	PHASE4
NCT07370220	COMPLETED	Ulcerative Colitis	Benha University	2025-02-22	PHASE2
NCT06579482	COMPLETED	Chronic Venous Insufficiency	Fundação Educacional Serra dos Órgãos	2024-11-06	PHASE4
NCT07518355	COMPLETED	Healthly Volunteers	China Medical University Hospital	2024-10-30
NCT07147842	COMPLETED	Ulcerative Colitis	Benha University	2024-11-01
NCT05387252	UNKNOWN	Vaccine Adverse Reaction; Side-Effect	Taipei Medical University	2022-05-31
NCT04955145	UNKNOWN	End Stage Renal Disease	Ain Shams University	2021-06-20	PHASE3
NCT04669977	UNKNOWN	Chemotherapy-induced Peripheral Neuropathy	Taipei Medical University	2020-12-02
NCT04161872	COMPLETED	Hyperuricemia	University of Pavia	2018-10-01	PHASE4
NCT03437902	COMPLETED	Type 2 Diabetes Mellitus	Ain Shams University	2018-02-24	PHASE2; PHASE3
NCT01847521	COMPLETED	Autism Spectrum Disorders	Attikon Hospital	2011-12	PHASE2
NCT00003365	TERMINATED	Colorectal Cancer	University of Medicine and Dentistry of New Jersey	1996-08
NCT01254006	COMPLETED	Glaucoma	University of Roma La Sapienza

(data from https://clinicaltrials.gov, updated on 2025-12-30)

Check the Rutin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Rutin targets cellular inflammatory mediators and scavenges reactive oxygen species, blocking downstream oxidative stress signaling pathways and preserving endothelial cell integrity. This cellular cytoprotection and attenuation of capillary fragility provide the mechanistic foundation for its clinical investigation in microvascular and metabolic conditions, including chronic venous insufficiency and type 2 diabetes mellitus.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).